Clinical relevance of depressed kynurenine pathway in episodic migraine patients: potential prognostic markers in the peripheral plasma during the interictal period

[1]  S. Rizvi,et al.  Age-dependent altered redox homeostasis in the chronodisrupted rat model and moderation by melatonin administration , 2020, Chronobiology international.

[2]  A. Carvalho,et al.  The association between melatonin and episodic migraine: a pilot network meta-analysis of randomized controlled trials to compare the prophylactic effects with exogenous melatonin supplementation and pharmacotherapy. , 2020, Journal of pineal research.

[3]  J. Ruas,et al.  The Kynurenine connection: how exercise shifts muscle tryptophan metabolism and affects energy homeostasis, the immune system, and the brain. , 2020, American journal of physiology. Cell physiology.

[4]  V. Macefield,et al.  Microstructural changes in the trigeminal nerve of patients with episodic migraine assessed using magnetic resonance imaging , 2020, The Journal of Headache and Pain.

[5]  L. Vécsei,et al.  A validated UHPLC-MS method for tryptophan metabolites: Application in the diagnosis of multiple sclerosis. , 2020, Journal of pharmaceutical and biomedical analysis.

[6]  D. McLoughlin,et al.  Tryptophan metabolite concentrations in depressed patients before and after electroconvulsive therapy , 2020, Brain, Behavior, and Immunity.

[7]  P. Klivényi,et al.  Neurotransmitter and tryptophan metabolite concentration changes in the complete Freund’s adjuvant model of orofacial pain , 2020, The Journal of Headache and Pain.

[8]  P. Chanson,et al.  Peripheral tryptophan, serotonin, kynurenine, and their metabolites in major depression: A case–control study , 2019, Psychiatry and clinical neurosciences.

[9]  J. Schoenen,et al.  The metabolic face of migraine — from pathophysiology to treatment , 2019, Nature Reviews Neurology.

[10]  I. Kema,et al.  Age‐ and disease‐specific changes of the kynurenine pathway in Parkinson’s and Alzheimer’s disease , 2019, Journal of neurochemistry.

[11]  Henrik Zetterberg,et al.  Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid-β and tau , 2019, Neurobiology of Aging.

[12]  E. Rota,et al.  Novelty in Inflammation and Immunomodulation in Migraine. , 2019, Current pharmaceutical design.

[13]  A. Hekmatdoost,et al.  The association between dietary tryptophan intake and migraine , 2019, Neurological Sciences.

[14]  L. Vécsei,et al.  The Opposite Effects of Kynurenic Acid and Different Kynurenic Acid Analogs on Tumor Necrosis Factor-α (TNF-α) Production and Tumor Necrosis Factor-Stimulated Gene-6 (TSG-6) Expression , 2019, Front. Immunol..

[15]  P. Conti,et al.  Progression in migraine: Role of mast cells and pro‐inflammatory and anti‐inflammatory cytokines☆ , 2019, European journal of pharmacology.

[16]  C. Svarer,et al.  Migraine is associated with high brain 5-HT levels as indexed by 5-HT4 receptor binding , 2018, Cephalalgia : an international journal of headache.

[17]  C. Ríos,et al.  Relevance of Alternative Routes of Kynurenic Acid Production in the Brain , 2018, Oxidative medicine and cellular longevity.

[18]  Qing-Song Xu,et al.  libPLS: An integrated library for partial least squares regression and linear discriminant analysis , 2018 .

[19]  J. Schoenen,et al.  Estrogen-dependent effects of 5-hydroxytryptophan on cortical spreading depression in rat: Modelling the serotonin-ovarian hormone interaction in migraine aura , 2018, Cephalalgia : an international journal of headache.

[20]  Á. Párdutz,et al.  Evidence for Plastic Processes in Migraine with Aura: A Diffusion Weighted MRI Study , 2018, Front. Neuroanat..

[21]  J. Tajti,et al.  Kynurenic Acid Inhibits the Electrical Stimulation Induced Elevated Pituitary Adenylate Cyclase-Activating Polypeptide Expression in the TNC , 2018, Front. Neurol..

[22]  A. Andersen,et al.  Changes in kynurenine pathway metabolism in Parkinson patients with L‐DOPA‐induced dyskinesia , 2017, Journal of neurochemistry.

[23]  G. Veres,et al.  The Effect of Systemic Nitroglycerin Administration on the Kynurenine Pathway in the Rat , 2017, Front. Neurol..

[24]  Á. Párdutz,et al.  Interictal brain activity differs in migraine with and without aura: resting state fMRI study , 2017, The Journal of Headache and Pain.

[25]  W. Turski,et al.  Influence of picolinic acid on seizure susceptibility in mice , 2017, Pharmacological reports : PR.

[26]  J. Toldi,et al.  Nitroglycerin enhances the propagation of cortical spreading depression: comparative studies with sumatriptan and novel kynurenic acid analogues , 2016, Drug design, development and therapy.

[27]  P. Goadsby,et al.  Metabotropic glutamate receptor 5: a target for migraine therapy , 2016, Annals of clinical and translational neurology.

[28]  F. Nicoletti,et al.  Altered kynurenine pathway metabolites in serum of chronic migraine patients , 2016, The Journal of Headache and Pain.

[29]  F. Nicoletti,et al.  Altered serum levels of kynurenine metabolites in patients affected by cluster headache , 2016, The Journal of Headache and Pain.

[30]  P. Girardi,et al.  Xanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a Potential Trait Marker for Schizophrenia , 2015, Scientific Reports.

[31]  J. Tajti,et al.  Drug targets of migraine and neuropathy: treatment of hyperexcitability. , 2015, CNS & neurological disorders drug targets.

[32]  W. Weckwerth,et al.  Iron chelation and redox chemistry of anthranilic acid and 3-hydroxyanthranilic acid: A comparison of two structurally related kynurenine pathway metabolites to obtain improved insights into their potential role in neurological disease development , 2015, Journal of organometallic chemistry.

[33]  W. Weckwerth,et al.  Effects of endogenous neurotoxin quinolinic acid on reactive oxygen species production by Fenton reaction catalyzed by iron or copper , 2015, Journal of organometallic chemistry.

[34]  P. Goadsby,et al.  Modulation of nociceptive dural input to the trigeminocervical complex through GluK1 kainate receptors , 2015, Pain.

[35]  J. Pedraza-Chaverri,et al.  The Janus faces of 3-hydroxykynurenine: Dual redox modulatory activity and lack of neurotoxicity in the rat striatum , 2014, Brain Research.

[36]  S. Masino,et al.  Ketogenic diet sensitizes glucose control of hippocampal excitability1 , 2014, Journal of Lipid Research.

[37]  C. Chow,et al.  Copper: toxicological relevance and mechanisms , 2014, Archives of Toxicology.

[38]  C. Wöber,et al.  Sufficiency and Necessity in Migraine: How do we Figure Out if Triggers are Absolute or Partial and, if Partial, Additive or Potentiating? , 2014, Current Pain and Headache Reports.

[39]  J. Pedraza-Chaverri,et al.  Kynurenines with Neuroactive and Redox Properties: Relevance to Aging and Brain Diseases , 2014, Oxidative medicine and cellular longevity.

[40]  G. Veres,et al.  Pre-treatment with new kynurenic acid amide dose-dependently prevents the nitroglycerine-induced neuronal activation and sensitization in cervical part of trigemino-cervical complex , 2014, Journal of Neural Transmission.

[41]  J. Toldi,et al.  Unexpected effects of peripherally administered kynurenic acid on cortical spreading depression and related blood–brain barrier permeability , 2013, Drug design, development and therapy.

[42]  J. Tajti,et al.  Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients , 2013, Cephalalgia : an international journal of headache.

[43]  J. Schoenen,et al.  Effect of systemic kynurenine on cortical spreading depression and its modulation by sex hormones in rat , 2012, Experimental Neurology.

[44]  G. Guillemin.  Quinolinic acid, the inescapable neurotoxin , 2012, The FEBS journal.

[45]  D. Levy.  Endogenous Mechanisms Underlying the Activation and Sensitization of Meningeal Nociceptors: The Role of Immuno-Vascular Interactions and Cortical Spreading Depression , 2012, Current Pain and Headache Reports.

[46]  L. Vécsei,et al.  The kynurenine system and immunoregulation , 2012, Journal of Neural Transmission.

[47]  M. Torres-Ramos,et al.  On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. , 2011, Neurotoxicology and teratology.

[48]  Sunhee C. Lee,et al.  The tryptophan metabolite 3-hydroxyanthranilic acid plays anti-inflammatory and neuroprotective roles during inflammation: role of hemeoxygenase-1. , 2011, The American journal of pathology.

[49]  Dan Levy,et al.  Activation of central trigeminovascular neurons by cortical spreading depression , 2011, Annals of neurology.

[50]  K. Lesch,et al.  5-hydroxyindolacetic acid (5-HIAA), a main metabolite of serotonin, is responsible for complete Freund's adjuvant-induced thermal hyperalgesia in mice , 2011, Molecular pain.

[51]  K. Zilles,et al.  Patterns of neurotransmitter receptor distributions following cortical spreading depression , 2009, Neuroscience.

[52]  G. Benedek,et al.  The Peripheral Antinociceptive Effects of Endomorphin-1 and Kynurenic Acid in the Rat Inflamed Joint Model , 2009, Anesthesia and analgesia.

[53]  J. Toldi,et al.  l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus , 2009, Neuropharmacology.

[54]  G. Smythe,et al.  The Physiological Action of Picolinic Acid in the Human Brain , 2009, International journal of tryptophan research : IJTR.

[55]  J. Toldi,et al.  The kynurenate analog SZR-72 prevents the nitroglycerol-induced increase of c-fos immunoreactivity in the rat caudal trigeminal nucleus: Comparative studies of the effects of SZR-72 and kynurenic acid , 2008, Neuroscience Research.

[56]  D. Aunis,et al.  Xanthurenic acid distribution, transport, accumulation and release in the rat brain , 2008, Journal of neurochemistry.

[57]  Gilles J Guillemin,et al.  Characterization of the Kynurenine Pathway in Human Neurons , 2007, The Journal of Neuroscience.

[58]  D. Mitsikostas,et al.  The role of glutamate and its receptors in migraine. , 2007, CNS & neurological disorders drug targets.

[59]  J. Toldi,et al.  Prevention of electrical stimulation-induced increase of c-fos immunoreaction in the caudal trigeminal nucleus by kynurenine combined with probenecid , 2007, Neuroscience Letters.

[60]  Y. Bayazıt,et al.  The A218C polymorphism of tryptophan hydroxylase gene and migraine , 2007, Journal of Clinical Neuroscience.

[61]  G. Leipnitz,et al.  In vitro evidence for an antioxidant role of 3-hydroxykynurenine and 3-hydroxyanthranilic acid in the brain , 2007, Neurochemistry International.

[62]  Yi-Zeng Liang,et al.  Plasma fatty acid metabolic profiling and biomarkers of type 2 diabetes mellitus based on GC/MS and PLS‐LDA , 2006, FEBS letters.

[63]  P. Drummond.  Tryptophan Depletion Increases Nausea, Headache and Photophobia in Migraine Sufferers , 2006, Cephalalgia : an international journal of headache.

[64]  D. Nutt,et al.  Tryptophan metabolism in the central nervous system: medical implications , 2006, Expert Reviews in Molecular Medicine.

[65]  E. Nagata,et al.  Plasma 5‐Hydroxytryptamine (5‐HT) in Migraine During an Attack‐Free Period , 2006, Headache.

[66]  P. Calabresi,et al.  Proinflammatory Cytokines, Adhesion Molecules, and Lymphocyte Integrin Expression in the Internal Jugular Blood of Migraine Patients Without Aura Assessed Ictally , 2006, Headache.

[67]  T. Stone,et al.  Tryptophan metabolism and oxidative stress in patients with Huntington's disease , 2005, Journal of neurochemistry.

[68]  J. Cipolla-Neto,et al.  Melatonin, 3 mg, is effective for migraine prevention , 2004, Neurology.

[69]  Kirk W. Johnson,et al.  LY293558, a Novel AMPA/GluR5 Antagonist, is Efficacious and Well-Tolerated in Acute Migraine , 2004, Cephalalgia : an international journal of headache.

[70]  J. Toldi,et al.  Kynurenine aminotransferase in the supratentorial dura mater of the rat: effect of stimulation of the trigeminal ganglion , 2004, Experimental Neurology.

[71]  R. Schwarcz,et al.  Cortical spreading depression augments kynurenate levels and reduces malonate toxicity in the rat cortex , 2004, Brain Research.

[72]  G. Juhász,et al.  Despite the general correlation of the serotonin transporter gene regulatory region polymorphism (5-HTTLPR) and platelet serotonin concentration, lower platelet serotonin concentration in migraine patients is independent of the 5-HTTLPR variants , 2003, Neuroscience Letters.

[73]  D. Dodick,et al.  Sustained-release niacin for prevention of migraine headache. , 2003, Mayo Clinic proceedings.

[74]  Zhi-qi Zhao,et al.  Kynurenic acid enhances electroacupuncture analgesia in normal and carrageenan-injected rats , 2003, Brain Research.

[75]  R. Schwarcz,et al.  Manipulation of Brain Kynurenines: Glial Targets, Neuronal Effects, and Clinical Opportunities , 2002, Journal of Pharmacology and Experimental Therapeutics.

[76]  D. Souza,et al.  Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes , 2002, Neurochemistry International.

[77]  M. Behbehani,et al.  Physiological characteristics of the projection pathway from the medial preoptic to the nucleus raphe magnus of the rat and its modulation by the periaqueductal gray , 2001, PAIN.

[78]  M. Weller,et al.  N‐[3,4‐dimethoxycinnamoyl]‐anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon‐γ (IFN‐γ) , 2001 .

[79]  S. Wold,et al.  PLS-regression: a basic tool of chemometrics , 2001 .

[80]  B. Brew,et al.  Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection , 2001, Journal of neurochemistry.

[81]  Y. Bayazıt,et al.  Association of the T102C polymorphism of 5-HT2A receptor gene with aura in migraine , 2001, Journal of the Neurological Sciences.

[82]  N Gelman,et al.  Periaqueductal Gray Matter Dysfunction in Migraine: Cause or the Burden of Illness? , 2001, Headache.

[83]  H. Diener,et al.  Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine , 2000, Neurology.

[84]  L. Chylack,et al.  3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. , 2000, Biochemistry.

[85]  T. Stone,et al.  Oxidative stress as a mechanism for quinolinic acid‐induced hippocampal damage: protection by melatonin and deprenyl , 1999, British journal of pharmacology.

[86]  R. Schwarcz,et al.  3‐Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum , 1999, The European journal of neuroscience.

[87]  K. Soliman,et al.  The analgesic effects of tryptophan and its metabolites in the rat. , 1998, Pharmacological research.

[88]  S. Murphy,et al.  Thalamic NMDA receptors modulate inflammation-produced hyperalgesia in the rat , 1997, Pain.

[89]  K. Welch,et al.  Platelet and Plasma Levels of Glutamate and Glutamine in Migraine With and Without Aura , 1995, Cephalalgia : an international journal of headache.

[90]  G. Chazot,et al.  Nocturnal Melatonin Excretion is Decreased in Patients With Migraine Without Aura Attacks Associated With Menses , 1995, Cephalalgia : an international journal of headache.

[91]  G. Murialdo,et al.  Urinary Melatonin Excretion Throughout the Ovarian Cycle in Menstrually Related Migraine , 1994, Cephalalgia : an international journal of headache.

[92]  R. Beninger,et al.  Picolinic acid modulates kainic acid-evoked glutamate release from the striatum in vitro , 1993, Brain Research.

[93]  J. Castillo,et al.  Neuroexcitatory Amino Acid Levels in Plasma and Cerebrospinal Fluid During Migraine Attacks , 1993, Cephalalgia : an international journal of headache.

[94]  R. Schwarcz,et al.  Blood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism , 1991, Journal of neurochemistry.

[95]  M. Ferrari,et al.  Neuroexcitatory plasma amino acids are elevated in migraine , 1990, Neurology.

[96]  M. Ferrari,et al.  Serotonin metabolism in migraine , 1989, Neurology.

[97]  G. Lynch,et al.  A Glycine Site Associated with N‐Methyl‐d‐Aspartic Acid Receptors: Characterization and Identification of a New Class of Antagonists , 1989, Journal of neurochemistry.

[98]  G. Chazot,et al.  Nocturnal Plasma Melatonin Levels in Migraine: A Preliminary Report , 1989, Headache.

[99]  R. Schwarcz,et al.  Identification and quantification of kynurenic acid in human brain tissue , 1988, Brain Research.

[100]  L. Knorring,et al.  5-HIAA and HVA in CSF in patients with idiopathic pain disorders , 1987, Biological Psychiatry.

[101]  P. Thomopoulos,et al.  The iron‐chelating agent picolinic acid enhances transferrin receptors expression in human erythroleukaemic cell lines , 1985, British journal of haematology.

[102]  J. Lance,et al.  Plasma serotonin in migraine and stress. , 1967, Archives of neurology.

[103]  F. Sicuteri,et al.  Biochemical Investigations in Headache: Increase in the Hydroxyindoleacetic Acid Excretion During Migraine Attacks , 1961 .

[104]  A. Friedman,et al.  Effect of serotonin in migraine patients , 1960, Neurology.

[105]  A. Friedman,et al.  Effect of serotonin in migraine patients , 1960, Neurology.

[106]  Per Magne Ueland,et al.  Kynurenine Pathway Metabolites in Alzheimer's Disease. , 2017, Journal of Alzheimer's disease : JAD.

[107]  G. Veres,et al.  A comparative assessment of two kynurenic acid analogs in the formalin model of trigeminal activation: a behavioral, immunohistochemical and pharmacokinetic study , 2016, Journal of Neural Transmission.

[108]  Reem A. Kanaan,et al.  A Comparative Study of Excitatory and Inhibitory Amino Acids in Three Different Brainstem Nuclei , 2007, Neurochemical Research.

[109]  J. Toldi,et al.  Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model , 2006, Journal of Neural Transmission.

[110]  J. Urenjak,et al.  Accumulation of quinolinic acid with neuroinflammation: does it mean excitotoxicity? , 2003, Advances in experimental medicine and biology.

[111]  M. Weller,et al.  N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon-gamma (IFN-gamma). , 2001, British journal of pharmacology.

[112]  H. Saito,et al.  Inhibitory effects of clonidine on serotonergic neuronal activity as measured by cerebrospinal fluid serotonin and its metabolite in anesthetized rats. , 1993, Life sciences.